Bain Capital Life Sciences Investors’s Panacea Acquisition Corp. II Class A Ordinary Shares PANA Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio PANA Stock Details PANA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-500,000	Closed	-$4.88M	–	35
2022 Q2	$4.88M	Hold	500,000	–	–	0.57%	30
2022 Q1	$4.88M	Hold	500,000	–	–	0.47%	29
2021 Q4	$4.85M	Hold	500,000	–	–	0.38%	29
2021 Q3	$4.88M	Hold	500,000	–	–	0.3%	28
2021 Q2	$5.01M	Buy	+500,000	New	+$5.01M	0.33%	26

Other funds holding PANA

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RCP

RIT Capital Partners London, United Kingdom $621M AUM 14.19% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.5% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Bain Capital Life Sciences Investors's PANA Position: Q3 2022 in Review

Bain Capital Life Sciences Investors sold out of Panacea Acquisition Corp. II Class A Ordinary Shares (PANA) in Q3 2022, closing a stake of 500,000 shares — an estimated $4.88M sold.

Bain Capital Life Sciences Investors first reported a position in PANA in Q2 2021 and held it in 5 quarters. The position peaked at $5.01M in Q2 2021. 49 funds tracked by Wall St. Rank hold PANA as of Q3 2022.

Bain Capital Life Sciences Investors reported no remaining Panacea Acquisition Corp. II Class A Ordinary Shares position as of Q3 2022 after selling out during the quarter.
Bain Capital Life Sciences Investors sold 500,000 Panacea Acquisition Corp. II Class A Ordinary Shares shares in Q3 2022, an estimated $4.88M.
Bain Capital Life Sciences Investors first reported a position in Panacea Acquisition Corp. II Class A Ordinary Shares in Q2 2021 and held it in 5 quarters.
Bain Capital Life Sciences Investors's Panacea Acquisition Corp. II Class A Ordinary Shares position peaked at $5.01M in Q2 2021.
49 funds tracked by Wall St. Rank held Panacea Acquisition Corp. II Class A Ordinary Shares as of Q3 2022.

Based on Bain Capital Life Sciences Investors's 13F filing for Q3 2022, filed 14 Nov 2022.